Recent Study: Oligonucleotide Synthesis Market - Global Forecast to 2019

Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019

The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. The global oligonucleotide synthesis market is categorized on the basis of products and services, applications, end users, and geography. The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos.

Full Report Details at
- http://www.fastmr.com/prod/879116_oligonucleotide_synthesis_market_global_forecast.aspx?afid=301

Major factors contributing to growth of the oligonucleotide synthesis market include growing R&D expenditure in pharmaceutical and biotech companies; emerging applications of oligos in molecular diagnostics and synthetic biology; and evolving significance of RNA-interference oligos in therapeutics and diagnostics. Furthermore, government support and venture capital funding are other major factors that will boost the growth of this market. For instance, the U.S. National Institutes of Health (NIH) spend $1.5 billion per year to support their oligonucleotide-based applications. Further, in January 2013, Solstice Biologics, a South California start-up, raised $18 million in a series-A financing backed by venture capital funding for targeting and delivery of nucleic acid therapeutics. The relatively-untapped markets of the Asia-Pacific (APAC) region and the increasing R&D activities and funding there have opened up an array of opportunities for the oligonucleotide synthesis market. However, factors such as regulatory barriers, especially for therapeutic oligos, and downward pricing pressure may restrain the growth of this market.

Apart from the comprehensive geographic and product analysis, and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by players in the industry over the last three years. In addition, the company profiles comprise the key players in the oligonucleotide synthesis market and their product portfolios, developments, and strategies. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output, in order to remain successful.

Reasons to Buy the Report:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Bring Your Own Device (BYOD) & Enterprise Mobility Market - Global Advancements, Market Forecast and Analysis (2014 - 2019)
- Mobile Device Management Market - Global Advancements, Market Forecast and Analysis (2014 - 2019)
- Unified Communication as a service (UCaaS) Market - Global Advancements, Worldwide Forecasts and Analysis (2014-2019)
- Converged Infrastructure Market - Worldwide Forecasts & Analysis (2014 - 2019)
- Mobile/Micro Data Center Market - Global Advancements, Worldwide Forecast & Analysis (2014-2019)